Sulforaphane mitigates muscle fibrosis in mdx mice via Nrf2-mediated inhibition of TGF-β/Smad signaling

Journal of Applied Physiology

Volumn 120, Issue 4, 2016, Pages 377-390

  Sun, Chengcao ^a   Li, Shujun ^a,b   Li, Dejia ^a  

^a WUHAN UNIVERSITY   (China)

^b Wuhan Hospital for Occupational Disease Prevention and Treatment   (China)

Author keywords

Duchenne muscular dystrophy; Fibrosis; Nrf2; Sulforaphane; TGF Smad

Indexed keywords

ACTIN; ALPHA-SMOOTH MUSCLE ACTIN, MOUSE; CD45 ANTIGEN; COLLAGEN TYPE 1; FIBRONECTIN; INTERLEUKIN 6; ISOTHIOCYANIC ACID DERIVATIVE; NFE2L2 PROTEIN, MOUSE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMAD PROTEIN; SULFORAFAN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ANIMAL; C57BL MOUSE; DRUG EFFECTS; FIBROSIS; MALE; METABOLISM; MOUSE; MUSCULAR DISEASES; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ACTINS; ANIMALS; ANTIGENS, CD45; COLLAGEN TYPE I; FIBRONECTINS; FIBROSIS; INTERLEUKIN-6; ISOTHIOCYANATES; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DISEASES; NF-E2-RELATED FACTOR 2; PLASMINOGEN ACTIVATOR INHIBITOR 1; SIGNAL TRANSDUCTION; SMAD PROTEINS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84959310400     PISSN: 87507587     EISSN: 15221601     Source Type: Journal    
DOI: 10.1152/japplphysiol.00721.2015     Document Type: Article

References (41)

1. Aleksunes LM, Manautou JE. Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease. Toxicol Pathol 35: 459-473, 2007.
2. Ardite E, Perdiguero E, Vidal B, Gutarra S, Serrano AL, Muñoz-Cánoves P. PAI-1-regulated miR-21 defines a novel age-associated fibro-genic pathway in muscular dystrophy. J Cell Biol 196: 163-175, 2012.
3. Benedetti S, Hoshiya H, Tedesco FS. Repair or replace? Exploiting novel gene and cell therapy strategies for muscular dystrophies. FEBS J 280: 4263-4280, 2013.
4. Bernasconi P, Di Blasi C, Mora M, Morandi L, Galbiati S, Confal-onieri P, Cornelio F, Mantegazza R. Transforming growth factor-beta1 and fibrosis in congenital muscular dystrophies. Neuromuscul Disord 9: 28-33, 1999.
5. Bernasconi P, Torchiana E, Confalonieri P, Brugnoni R, Barresi R, Mora M, Cornelio F, Morandi L, Mantegazza R. Expression of trans-forming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. J Clin Invest 96: 1137-1144, 1995.
6. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 331: 1286-1292, 1994.
7. Briggs D, Morgan JE. Recent progress in satellite cell/myoblast engraft-ment-relevance for therapy. FEBS J 280: 4281-4293, 2013.
8. Chen YW, Nagaraju K, Bakay M, McIntyre O, Rawat R, Shi R, Hoffman EP. Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology 65: 826-834, 2005.
9. Sun C, Yang C, Xue R, Li S, Zhang T, Pan L, Ma X, Wang L, Li D. Sulforaphane alleviates muscular dystrophy in mdx mice by activation of Nrf2. J Appl Physiol 118: 224-237, 2015.
10. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, Gamradt M, Ap RC, Holm TM, Loeys BL, Ramirez F, Judge DP, Ward CW, Dietz HC. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 13: 204-210, 2007.
11. Emery AE. The muscular dystrophies. Lancet 359: 687-695, 2002.
12. Fassett J, Zhang P, Zhao B, Chen Y, Lu Z, Xu X, Hu X, Zhu G, Tao Y, Li J. PGC-1 alpha regulates expression of myocardial mitochondrial antioxidants and myocardial oxidative stress after chronic systolic overload. Antioxid Redox Signal 13: 1011-1022, 2010.
13. Gosselin LE, Williams JE, Deering M, Brazeau D, Koury S, Martinez DA. Localization and early time course of TGF-beta 1 mRNA expression in dystrophic muscle. Muscle Nerve 30: 645-653, 2004.
14. Granot I, Bartov I, Plavnik I, Wax E, Hurwitz S, Pines M. Increased skin tearing in broilers and reduced collagen synthesis in skin in vivo and in vitro in response to the coccidiostat halofuginone. Poult Sci 70: 1559-1563, 1991.
15. Hori YS, Kuno A, Hosoda R, Tanno M, Miura T, Shimamoto K, Horio Y. Resveratrol ameliorates muscular pathology in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy. J Pharmacol Exp Ther 338: 784-794, 2011.
16. Huebner KD, Jassal DS, Halevy O, Pines M, Anderson JE. Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone. Am J Physiol Heart Circ Physiol 294: H1550-H1561, 2008.
17. Johnson RJ, Floege J, Couser WG, Alpers CE. Role of platelet-derived growth factor in glomerular disease. J Am Soc Nephrol 4: 119-128, 1993.
18. Jorgensen LH, Blain A, Greally E, Laval SH, Blamire AM, Davison BJ, Brinkmeier H, MacGowan GA, Schroder HD, Bushby K, Straub V, Lochmuller H. Long-term blocking of calcium channels in mdx mice results in differential effects on heart and skeletal muscle. Am J Pathol 178: 273-283, 2011.
19. Juge N, Mithen RF, Traka M. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol Life Sci 64: 1105-1127, 2007.
20. Jung KA, Kwak MK. The Nrf2 system as a potential target for the development of indirect antioxidants. Molecules 15: 7266-7291, 2010.
21. Kelly DJ, Gilbert RE, Cox AJ, Soulis T, Jerums G, Cooper ME. Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol 12: 2098-2107, 2001.
22. Kollias HD, McDermott JC. Transforming growth factor-beta and myo-statin signaling in skeletal muscle. J Appl Physiol 104: 579-587, 2008.
23. Konieczny P, Swiderski K, Chamberlain JS. Gene and cell-mediated therapies for muscular dystrophy. Muscle Nerve 47: 649-663, 2013.
24. Leung DG, Wagner KR. Therapeutic advances in muscular dystrophy. Ann Neurol 74: 404-411, 2013.
25. Levi O, Genin O, Angelini C, Halevy O, Pines M. Inhibition of muscle fibrosis results in increases in both utrophin levels and the number of revertant myofibers in Duchenne muscular dystrophy. Oncotarget 6: 23249-23260, 2015.
26. Meregalli M, Farini A, Belicchi M, Parolini D, Cassinelli L, Razini P, Sitzia C, Torrente Y. Perspectives of stem cell therapy in Duchenne muscular dystrophy. FEBS J 280: 4251-4262, 2013.
27. Nakaso K, Yano H, Fukuhara Y, Takeshima T, Wada-Isoe K, Na-kashima K. PI3K is a key molecule in the Nrf2-mediated regulation of antioxidative proteins by hemin in human neuroblastoma cells. FEBS Lett 546: 181-184, 2003.
28. Oh CJ, Kim JY, Min AK, Park KG, Harris RA, Kim HJ, Lee IK. Sulforaphane attenuates hepatic fibrosis via NF-E2-related factor 2-medi-ated inhibition of transforming growth factor-beta/Smad signaling. Free Radic Biol Med 52: 671-682, 2012.
29. Prud'Homme GJ. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 87: 1077-1091, 2007.
30. Ruegg UT. Pharmacological prospects in the treatment of Duchenne muscular dystrophy. Curr Opin Neurol 26: 577-584, 2013.
31. Shin DH, Park HM, Jung KA, Choi HG, Kim JA, Kim DD, Kim SG, Kang KW, Ku SK, Kensler TW, Kwak MK. The NRF2-heme oxygenase-1 system modulates cyclosporin A-induced epithelial-mesenchymal transition and renal fibrosis. Free Radic Biol Med 48: 1051-1063, 2010.
32. Sun C, Yang C, Xue R, Li S, Zhang T, Pan L, Ma X, Wang L, Li D. Sulforaphane alleviates muscular dystrophy in mdx mice by activation of Nrf2. J Appl Physiol 118: 224-237, 2015.
33. Sun CC, Li SJ, Yang CL, Xue RL, Xi YY, Wang L, Zhao QL, Li DJ. Sulforaphane attenuates muscle inflammation in dystrophin-deficient mice via NF-E2-related factor 2 (Nrf2)-mediated inhibition of NF-KB signaling pathway. J Biol Chem 290: 17784-17795, 2015.
34. Tsai PY, Ka SM, Chao TK, Chang JM, Lin SH, Li CY, Kuo MT, Chen P, Chen A. Antroquinonol reduces oxidative stress by enhancing the Nrf2 signaling pathway and inhibits inflammation and sclerosis in focal segmental glomerulosclerosis mice. Free Radic Biol Med 50: 1503-1516, 2011.
35. Turgeman T, Hagai Y, Huebner K, Jassal DS, Anderson JE, Genin O, Nagler A, Halevy O, Pines M. Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone. Neuromuscul Disord 18: 857-868, 2008.
36. Vidal B, Serrano AL, Tjwa M, Suelves M, Ardite E, De Mori R, Baeza-Raja B, Martínez de Legrán M, Lafuste P, Ruiz-Bonilla V, Jardi M, Gherardi R, Christov C, Dierssen M, Carmeliet P, Degen JL, Dewerchin M, Muñoz-Cánoves P. Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative macrophage activation pathway. Genes Dev 22: 1747-1752, 2008.
37. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 214: 199-210, 2008.
38. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 117: 524-529, 2007.
39. Zhang Y, Talalay P, Cho CG, Posner GH. A major inducer of anticar-cinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci USA 89: 2399-2403, 1992.
40. Zhou L, Porter JD, Cheng G, Gong B, Hatala DA, Merriam AP, Zhou X, Rafael JA, Kaminski HJ. Temporal and spatial mRNA expression patterns of TGF-beta1, 2, 3 and TbetaRI, II, III in skeletal muscles of mdx mice. Neuromuscul Disord 16: 32-38, 2006.
41. Zhou L, Lu H. Targeting fibrosis in Duchenne muscular dystrophy. J Neuropathol Exp Neurol 69: 771-776, 2010.